FTD is one of the most common forms of dementia in patients as young as 40 years old. More than half of FTD patients will experience behavioral changes associated with the progression of FTD. Symptoms of FTD can vary, but most patients exhibit personality changes and may demonstrate a progressive decline in socially appropriate behavior.
FTD is often misdiagnosed as other common types of neurological diseases such as Alzheimer’s. According to The Association for Frontotemporal Degeneration, on average it takes 3.6 years for patients to receive an accurate diagnosis. There are currently no approved treatment options for FTD.
The era of mindful medicine is here:
PSIL-006
Design & Pr0mise:
PSIL-006 is a next-generation, psilocybin derivative with broad applicability and a patient-friendly profile. Because of its non-hallucinogenic profile, PSIL-006 is designed to be a good candidate for take-home use and insurability.
Preclinical Data Shows:
- PSIL-006 has demonstrated no treatment-limiting side effects, such as hallucinations.
- Animal model testing demonstrated efficacy with a single dose by reducing several symptoms commonly associated with FTD.
- PSIL-006 has demonstrated a positive effect on serotonin receptor 2A (5-HT2A) which is commonly targeted in the brain for the rapid treatment of psychiatric conditions.
